Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
José Luís Piñana, Lourdes Vázquez, Marisa Calabuig, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1699-1721
Closed Access | Times Cited: 28
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review
Sylvia Mink, Patrick Reimann, Peter Fraunberger
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 6, pp. 1029-1043
Open Access | Times Cited: 9
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE
Xuan Wang, Ankit Pahwa, Mary T. Bausch-Jurken, et al.
Advances in Therapy (2025)
Open Access | Times Cited: 1
A Machine Learning approach to identify groups of patients with hematological malignant disorders
Pablo Rodríguez-Belenguer, José Luís Piñana, Manuel Sánchez-Montañés, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 246, pp. 108011-108011
Open Access | Times Cited: 5
Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection
Emilie Goguet, Cara Olsen, William A. Meyer, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients
Yana Debie, Irene Garcia-Fogeda, Lander Willem, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Comparative Effectiveness of the mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults With Underlying Medical Conditions: A Systematic Literature Review and Pairwise Meta-Analysis Using GRADE
Xuan Wang, Ankit Pahwa, Mary T. Bausch-Jurken, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 3
Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances
José Luís Piñana, Ariadna Pérez, Pedro Chorão, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 8
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
José Luís Piñana, Inmaculada Heras, Tommaso Francesco Aiello, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 2066-2066
Open Access | Times Cited: 8
A Pictorial Essay Describing the CT Imaging Features of COVID-19 Cases throughout the Pandemic with a Special Focus on Lung Manifestations and Extrapulmonary Vascular Abdominal Complications
Barbara Brogna, Elio Bignardi, A. Megliola, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2113-2113
Open Access | Times Cited: 7
Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies
Tzong‐Yow Wu, Wan-Ting Tsai, Kai-Hsiang Chen, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 3, pp. 403-413
Open Access | Times Cited: 2
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
José Luís Piñana, Lourdes Vázquez, Inmaculada Heras, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, et al.
Current Oncology (2023) Vol. 30, Iss. 5, pp. 5103-5115
Open Access | Times Cited: 5
The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review
SeyedAhmad SeyedAlinaghi, Mohsen Dashti, Arian Afzalian, et al.
Preventive Medicine Reports (2024) Vol. 44, pp. 102778-102778
Open Access | Times Cited: 1
SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?
José Luís Piñana, Manuel Guerreiro, Carlos Solano
Hemato (2023) Vol. 4, Iss. 2, pp. 170-183
Open Access | Times Cited: 3
Antibody responses to SARS‐CoV‐2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort study
Jun Li, Yi Liu, Xia Wei, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 3
Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient
James P. Long, Mithil Soni, Pawel Muranski, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1
Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV‐2 Omicron in patients with haematological malignancies: A national prospective cohort study
Lukas Kevličius, Karolis Šablauskas, Kazimieras Maneikis, et al.
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 497-506
Open Access | Times Cited: 1
COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation—A Single-Center Study
Lina Souan, Hikmat Abdel‐Razeq, Sura Nashwan, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1659-1659
Open Access | Times Cited: 1
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial
Laurie Spehner, Émeline Orillard, Antoine Falcoz, et al.
BMJ Oncology (2023) Vol. 2, Iss. 1, pp. e000054-e000054
Open Access | Times Cited: 1
Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature
John Asimakopoulos, Eleni Lalou, George Seferlis, et al.
Hematology Reports (2024) Vol. 16, Iss. 2, pp. 220-233
Open Access
The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia
Shenmiao Yang, Rong Wei, Hongxia Shi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants.
Holly E. Baum, Marianna Santopaolo, Ore Francis, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Carga de la COVID-19 variante ómicron en pacientes inmunocomprometidos en España: revisión sistemática
Raúl Ortiz-de-Lejarazu, Borja Quiroga, Alberto López García
Medicina Clínica (2024) Vol. 163, Iss. 7, pp. 347-359
Open Access
Page 1 - Next Page

Scroll to top